SV-1993

SV-1993 is an orally bioavailable small molecule inhibitor of Ubiquitin-Specific Protease 1 (USP1), currently under development by Beijing Senmiao Biological Technology for the treatment of advanced solid tumors. USP1 is a deubiquitinating enzyme that plays a critical role in DNA damage repair pathways, specifically by regulating the ubiquitination status of substrates like PCNA and FANCD2. By inhibiting USP1, SV-1993 disrupts these repair mechanisms, leading to the accumulation of DNA damage and inducing synthetic lethality in cancer cells, particularly those with homologous recombination deficiency (HRD). Preclinical evidence suggests that USP1 inhibition can also sensitize tumors to PARP inhibitors and potentially overcome resistance to such therapies. SV-1993 is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced solid tumors.